Parkinson's disease (PD) is a neurodegenerative disorder with multifaceted aspects that requires a comprehensive understanding for effective management.
PD is primarily characterized by the degeneration of dopaminergic neurons in the substantia nigra. The exact etiology remains unclear, however, genetic predispositions, environmental factors, and aging are considered key contributors.
PD manifests with motor symptoms such as bradykinesia, rigidity, and tremors. Non-motor symptoms including cognitive impairment, mood disorders, and autonomic dysfunction are also prevalent.
Diagnosis relies on clinical criteria, with neuroimaging serving as a supportive tool. Management involves pharmacological interventions, primarily levodopa, and non-pharmacological strategies.
PD is a progressive disease with varying prognoses. Research is ongoing to develop more effective treatments and ultimately, a cure.
Understanding the multifaceted aspects of PD is crucial for its diagnosis and management. Continuous research is required to further elucidate the pathogenesis and develop more effective therapeutic strategies.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation